Anhye Kim, Dongseong Shin, Youlim Seo, Deborah Kang, Yang Won Min, In Hee Kim, Jungryul Kim
{"title":"Phase I Study to Evaluate the Effect of Hepatic Impairment on Pharmacokinetics and Safety of Tegoprazan, a Potassium Competitive Acid Blocker","authors":"Anhye Kim, Dongseong Shin, Youlim Seo, Deborah Kang, Yang Won Min, In Hee Kim, Jungryul Kim","doi":"10.1007/s12325-025-03127-5","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Tegoprazan is a potassium-competitive acid blocker, and its systemic exposure is presumably affected by hepatic clearance and bioavailability. This study aimed to investigate the effect of hepatic impairment (HI) on the safety and pharmacokinetics of tegoprazan and metabolite.</p><h3>Methods</h3><p>An open-label, multicenter, parallel-group study was conducted in patients with mild (<i>n</i> = 8), moderate (<i>n</i> = 8) and severe (<i>n</i> = 1) HI according to the Child–Pugh classification as well as controls. Healthy subjects (<i>n</i> = 8) were matched to patients with the moderate category based on age, body mass index and sex. Blood and urine samples were obtained to evaluate the concentrations of tegoprazan and metabolite (M1) until 48 h after a single oral administration of 50 mg of tegoprazan.</p><h3>Results</h3><p>The geometric mean ratio with a 90% confidence interval of maximum plasma concentration and area under the plasma concentration–time curve for tegoprazan in patients with impaired hepatic function compared to controls were 0.8228 (0.4997–1.3550) and 1.2264 (0.7447–2.0197) in the mild category, 1.0332 (0.6274–1.7015) and 1.7676 (1.0733–2.9109) in the moderate category, and 1.0699 (0.3713–3.0823) and 1.9567 (0.6792–5.6377) in the severe category. The half-life, apparent clearance, renal clearance, and fraction unbound to plasma protein were comparable across study groups. The plasma concentration of M1 increased and decreased faster in the normal group. Tegoprazan was generally well tolerated in patients with HI.</p><h3>Conclusions</h3><p>Systemic exposure to tegoprazan tended to be increased in subjects with HI. The difference between patients with mild HI and the controls was deemed not to require dose adjustment for tegoprazan.</p><h3>Clinical Trial Registration</h3><p>ClinicalTrials.gov identifiers: NCT04494269 (31 Jul 2020).</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 3","pages":"1570 - 1581"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-025-03127-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Tegoprazan is a potassium-competitive acid blocker, and its systemic exposure is presumably affected by hepatic clearance and bioavailability. This study aimed to investigate the effect of hepatic impairment (HI) on the safety and pharmacokinetics of tegoprazan and metabolite.
Methods
An open-label, multicenter, parallel-group study was conducted in patients with mild (n = 8), moderate (n = 8) and severe (n = 1) HI according to the Child–Pugh classification as well as controls. Healthy subjects (n = 8) were matched to patients with the moderate category based on age, body mass index and sex. Blood and urine samples were obtained to evaluate the concentrations of tegoprazan and metabolite (M1) until 48 h after a single oral administration of 50 mg of tegoprazan.
Results
The geometric mean ratio with a 90% confidence interval of maximum plasma concentration and area under the plasma concentration–time curve for tegoprazan in patients with impaired hepatic function compared to controls were 0.8228 (0.4997–1.3550) and 1.2264 (0.7447–2.0197) in the mild category, 1.0332 (0.6274–1.7015) and 1.7676 (1.0733–2.9109) in the moderate category, and 1.0699 (0.3713–3.0823) and 1.9567 (0.6792–5.6377) in the severe category. The half-life, apparent clearance, renal clearance, and fraction unbound to plasma protein were comparable across study groups. The plasma concentration of M1 increased and decreased faster in the normal group. Tegoprazan was generally well tolerated in patients with HI.
Conclusions
Systemic exposure to tegoprazan tended to be increased in subjects with HI. The difference between patients with mild HI and the controls was deemed not to require dose adjustment for tegoprazan.
期刊介绍：
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
